Literature DB >> 18621092

Role of biotransformation in 3-(3,5-dichlorophenyl)-2,4-thiazolidinedione-induced hepatotoxicity in Fischer 344 rats.

Christine M Crincoli1, Niti N Patel, Ruy Tchao, Peter J Harvison.   

Abstract

Cytochrome P450 (CYP)-mediated metabolism in the thiazolidinedione (TZD) ring may contribute to the hepatotoxicity of the insulin-sensitizing agents such as troglitazone. We were interested in determining if biotransformation could also be a factor in the liver damage associated with another TZD ring containing compound, 3-(3,5-dichlorophenyl)-2,4-thiazolidinedione (DCPT). Therefore, hepatotoxic doses of DCPT (0.6 or 1.0 mmol/kg, i.p.) were administered to male Fischer 344 rats after pretreatment with vehicle, 1-aminobenzotriazole (ABT, non-selective CYP inhibitor) and troleandomycin (TAO, CYP3A inhibitor). Alternatively, rats were pretreated with vehicle or the CYP3A inducer dexamethasone (DEX) prior to a non-toxic DCPT dose (0.2 mmol/kg, i.p.). Vehicle-, ABT-, TAO- and DEX-only control groups were also run. Toxicity was assessed 24 h after DCPT administration. Both hepatotoxic doses of DCPT induced elevations in serum alanine aminotransferase (ALT) levels that were attenuated by ABT or TAO pretreatment. Liver sections from rats that received vehicle+DCPT revealed areas of gross necrosis and neutrophil invasion, whereas sections from ABT+DCPT and TAO+DCPT rats showed minor changes compared to controls. DEX pretreatment potentiated ALT levels associated with the non-toxic DCPT dose. Furthermore, DEX+DCPT rat liver sections exhibited hepatic injury when compared against rats that received vehicle+DCPT. Blood urea nitrogen levels, urinalysis and kidney morphology were not markedly altered by any combination of pretreatments or treatments. Enzyme activity and Western blotting experiments with rat liver microsomes confirmed the effects of the various pretreatments. Our results suggest that hepatic CYP3A isozymes may be involved in DCPT-induced liver damage in male rats. We believe this is the first report demonstrating that modulation of the biotransformation of a TZD ring-containing compound can alter hepatotoxicity in a common animal model.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18621092      PMCID: PMC2570351          DOI: 10.1016/j.tox.2008.06.006

Source DB:  PubMed          Journal:  Toxicology        ISSN: 0300-483X            Impact factor:   4.221


  37 in total

1.  Liver failure in a patient treated with long-term rosiglitazone therapy.

Authors:  H E Gouda; A Khan; J Schwartz; R I Cohen
Journal:  Am J Med       Date:  2001-11       Impact factor: 4.965

Review 2.  Lessons from the glitazones: a story of drug development.

Authors:  E A Gale
Journal:  Lancet       Date:  2001-06-09       Impact factor: 79.321

3.  Hepatocellular injury in a patient receiving pioglitazone.

Authors:  K Maeda
Journal:  Ann Intern Med       Date:  2001-08-21       Impact factor: 25.391

Review 4.  Hepatotoxicity with thiazolidinediones: is it a class effect?

Authors:  A J Scheen
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 5.  Human drug metabolism and the cytochromes P450: application and relevance of in vitro models.

Authors:  K Venkatakrishnan; L L Von Moltke; D J Greenblatt
Journal:  J Clin Pharmacol       Date:  2001-11       Impact factor: 3.126

6.  Hepatic glycogen staining. Applications in injury survival time and child abuse.

Authors:  J R Thogmartin; D England; C F Siebert
Journal:  Am J Forensic Med Pathol       Date:  2001-09       Impact factor: 0.921

7.  Enzyme-induction dependent bioactivation of troglitazone and troglitazone quinone in vivo.

Authors:  J N Tettey; J L Maggs; W G Rapeport; M Pirmohamed; B K Park
Journal:  Chem Res Toxicol       Date:  2001-08       Impact factor: 3.739

8.  Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission.

Authors:  K Kassahun; P G Pearson; W Tang; I McIntosh; K Leung; C Elmore; D Dean; R Wang; G Doss; T A Baillie
Journal:  Chem Res Toxicol       Date:  2001-01       Impact factor: 3.739

9.  Synthesis and aldose reductase inhibitory activity of 5-arylidene-2,4-thiazolidinediones.

Authors:  G Bruno; L Costantino; C Curinga; R Maccari; F Monforte; F Nicoló; R Ottanà; M G Vigorita
Journal:  Bioorg Med Chem       Date:  2002-04       Impact factor: 3.641

10.  Nephrotoxic and hepatotoxic potential of imidazolidinedione-, oxazolidinedione- and thiazolidinedione-containing analogues of N-(3,5-dichlorophenyl)succinimide (NDPS) in Fischer 344 rats.

Authors:  Erica L Kennedy; Ruy Tchao; Peter J Harvison
Journal:  Toxicology       Date:  2003-04-15       Impact factor: 4.221

View more
  6 in total

1.  Cytotoxicity of 3-(3,5-dichlorophenyl)-2,4-thiazolidinedione (DCPT) and analogues in wild type and CYP3A4 stably transfected HepG2 cells.

Authors:  Douglas M Frederick; Erina Y Jacinto; Niti N Patel; Thomas H Rushmore; Ruy Tchao; Peter J Harvison
Journal:  Toxicol In Vitro       Date:  2011-09-22       Impact factor: 3.500

2.  Effect of structural modifications on 3-(3,5-dichlorophenyl)-2,4-thiazolidinedione-induced hepatotoxicity in Fischer 344 rats.

Authors:  Niti N Patel; Christine M Crincoli; Douglas M Frederick; Ruy Tchao; Peter J Harvison
Journal:  J Appl Toxicol       Date:  2011-02-21       Impact factor: 3.446

3.  Exposure to difenoconazole, diclofop-methyl alone and combination alters oxidative stress and biochemical parameters in albino rats.

Authors:  Sherif H Abd-Alrahman; Manal Ea Elhalwagy; Gamila Ahmed Kotb; Hoda Farid; Ahmed Ag Farag; Hossam M Draz; Ahmed M Isa; S Sabico
Journal:  Int J Clin Exp Med       Date:  2014-10-15

4.  Cytotoxicity of thiazolidinedione-, oxazolidinedione- and pyrrolidinedione-ring containing compounds in HepG2 cells.

Authors:  Alyssa M Keil; Douglas M Frederick; Erina Y Jacinto; Erica L Kennedy; Randy J Zauhar; Nathan M West; Ruy Tchao; Peter J Harvison
Journal:  Toxicol In Vitro       Date:  2015-07-17       Impact factor: 3.500

5.  A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma.

Authors:  Ying-Wei Lin; Zanna M Beharry; Elizabeth G Hill; Jin H Song; Wenxue Wang; Zuping Xia; Zhenhua Zhang; Peter D Aplan; Jon C Aster; Charles D Smith; Andrew S Kraft
Journal:  Blood       Date:  2009-11-23       Impact factor: 22.113

6.  1-Aminobenzotriazole: A Mechanism-Based Cytochrome P450 Inhibitor and Probe of Cytochrome P450 Biology.

Authors:  Paul R Ortiz de Montellano
Journal:  Med Chem (Los Angeles)       Date:  2018-03-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.